Global Immuno-oncology Drugs Market Growth, Share, Size, Trends and Forecast (2025 - 2031)

By Treatment Type;

Immune Checkpoint Inhibitors, Immune System Modulators, Cancer Vaccines, and Oncolytic Virus.

By Distribution Channel;

Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies.

By Drug Type;

Immune Checkpoint Inhibitors, Monoclonal Antibodies, Cytokine Based Immunotherapy, Cancer Vaccines, and CAR-T Cell Therapy.

By Cancer Type;

Non-Small Cell Lung Cancer, Acute Myeloid Leukemia, Lymphoma, Multiple Myeloma, Breast Cancer, Ovarian Cancer, Prostate Cancer, Colorectal Cancer, Gastric Cancers, Glioblastoma, and Head & Neck Cancers.

By Geography;

North America, Europe, Asia Pacific, Middle East and Africa, and Latin America - Report Timeline (2021 - 2031).
Report ID: Rn154376519 Published Date: January, 2025 Updated Date: February, 2025

Introduction

Global Immuno-oncology Drugs Market (USD Million), 2021 - 2031

In the year 2024, the Global Immuno-oncology Drugs Market was valued at USD 19,306.48 million. The size of this market is expected to increase to USD 43,786.24 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 12.4%.

The global immuno-oncology drugs market represents a groundbreaking frontier in cancer treatment, leveraging the body's own immune system to combat cancer cells. Immuno-oncology drugs, also known as cancer immunotherapy, have transformed the landscape of cancer care by offering novel therapeutic approaches that harness the power of the immune system to recognize and eradicate tumors.

Global immuno-oncology drugs market is witnessing rapid growth driven by several factors, including increasing cancer prevalence, growing awareness of immunotherapy's potential, and ongoing advancements in biotechnology and cancer research. With an expanding portfolio of approved drugs and promising candidates in clinical development, the immuno-oncology market offers new hope for patients with a wide range of cancers, including melanoma, lung cancer, bladder cancer, and hematological malignancies.

Immuno-oncology field continues to evolve and mature, the global market is poised for further expansion, fueled by ongoing research efforts, strategic collaborations, and regulatory approvals. Immuno-oncology drugs represent a paradigm shift in cancer treatment, offering personalized and potentially curative therapies that target cancer cells while sparing healthy tissues. With continued innovation and investment, immuno-oncology drugs are expected to play an increasingly prominent role in the future of cancer care, driving improvements in patient outcomes and transforming the standard of care for cancer patients worldwide.

  1. Introduction
    1. Research Objectives and Assumptions
    2. Research Methodology
    3. Abbreviations
  2. Market Definition & Study Scope
  3. Executive Summary
    1. Market Snapshot, By Treatment Type
    2. Market Snapshot, By Distribution Channel
    3. Market Snapshot, By Drug Type
    4. Market Snapshot, By Cancer Type
    5. Market Snapshot, By Region
  4. Global Immuno-oncology Drugs Market Dynamics
    1. Drivers, Restraints and Opportunities
      1. Drivers
        1. Growing Incidence of Cancer
        2. Advancements in Immunotherapy
        3. Rising Demand for Targeted Therapies
        4. Expansion of Indications for Immuno-oncology Drugs
      2. Restraints
        1. High Cost of Treatment
        2. Limited Efficacy in Some Patients
        3. Immune-related Adverse Events
        4. Complexity of Combination Therapies
      3. Opportunities
        1. Expansion into Emerging Markets
        2. Development of Novel Combination Therapies
        3. Focus on Biomarker-driven Approaches
        4. Personalized Treatment Strategies
    2. PEST Analysis
      1. Political Analysis
      2. Economic Analysis
      3. Social Analysis
      4. Technological Analysis
    3. Porter's Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of Substitutes
      4. Threat of New Entrants
      5. Competitive Rivalry
  5. Market Segmentation
    1. Global Immuno-oncology Drugs Market, By Treatment Type, 2021 - 2031 (USD Million)
      1. Immune Checkpoint Inhibitors
      2. Immune System Modulators
      3. Cancer Vaccines
      4. Oncolytic Virus
    2. Global Immuno-oncology Drugs Market, By Distribution Channel, 2021 - 2031 (USD Million)
      1. Hospital Pharmacies
      2. Retail Pharmacies
      3. Online Pharmacies
    3. Global Immuno-oncology Drugs Market, By Drug Type, 2021 - 2031 (USD Million)
      1. Immune Checkpoint Inhibitors
      2. Monoclonal Antibodies
      3. Cytokine Based Immunotherapy
      4. Cancer Vaccines
      5. CAR-T Cell Therapy
    4. Global Immuno-oncology Drugs Market, By Cancer Type, 2021 - 2031 (USD Million)
      1. Non-Small Cell Lung Cancer
      2. Acute Myeloid Leukemia
      3. Lymphoma
      4. Multiple Myeloma
      5. Breast Cancer
      6. Ovarian Cancer
      7. Prostate Cancer
      8. Colorectal Cancer
      9. Gastric Cancers
      10. Glioblastoma
      11. Head & Neck Cancers
    5. Global Immuno-oncology Drugs Market, By Geography, 2021 - 2031 (USD Million)
      1. North America
        1. United States
        2. Canada
      2. Europe
        1. Germany
        2. United Kingdom
        3. France
        4. Italy
        5. Spain
        6. Nordic
        7. Benelux
        8. Rest of Europe
      3. Asia Pacific
        1. Japan
        2. China
        3. India
        4. Australia & New Zealand
        5. South Korea
        6. ASEAN (Association of South East Asian Countries)
        7. Rest of Asia Pacific
      4. Middle East & Africa
        1. GCC
        2. Israel
        3. South Africa
        4. Rest of Middle East & Africa
      5. Latin America
        1. Brazil
        2. Mexico
        3. Argentina
        4. Rest of Latin America
  6. Competitive Landscape
    1. Company Profiles
      1. Amgen
      2. Astra Zeneca
      3. Bristol-Myers Squib
      4. Celgene Corporation
      5. Johnson & Johnson
      6. Novartis International
      7. EMD Serono
      8. Gilead Sciences
      9. Prometheus Therapeutics & Diagnostics
  7. Analyst Views
  8. Future Outlook of the Market